Pfizer to bring long-lasting liquid DXM to market

MONMOUTH JUNCTION, N.J. - Tris Pharma on Monday announced that Pfizer Consumer Healthcare will commercialize the company's extended release dextromethorphan cough syrup under the Robitussin brand beginning in July. 

 

In exchange, Tris will receive an upfront payment, milestone payments and sales-based royalties. Tris will be responsible for manufacturing and regulatory activities while Pfizer Consumer Healthcare will manage sales, marketing and distribution.

 

"The U.S. cough and cold market has been ripe for innovation and when you consider that market research shows most patients prefer long-lasting relief in the form of a liquid, rather than a solid pill, our technology is well positioned to address this market," stated Ketan Mehta, Tris CEO.